Advocacy groups form a buyer’s club to obtain generic versions of pricey Vertex cystic fibrosis drug
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
Generic versions of biologic drugs could hit the market without human trials and allow the market forces to bring down costs, ...
People don't like online forms (gasp!). And it's not hard to see why: Online forms require extra work (and time) and typically stand in the way of a consumer's getting what he or she really wants—such ...
KING OF PRUSSIA, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results ...
Zacks Investment Research on MSN
Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
We expect Vertex Pharmaceuticals VRTX to surpass expectations when it reports its third-quarter 2025 results on Nov. 3, after ...
Tech stocks and top consumer names are increasingly at risk of steep declines in a slowing economy. Click here to see 5 ...
Alphabet-owned Google has agreed to invest a multimillion-pound sum in an instrument which could convert into an equity stake ...
Q3 2025 Earnings Call Transcript October 29, 2025 Alphabet Inc. beats earnings expectations. Reported EPS is $2.87, ...
Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback